# EDGAR Filing Document

**Accession Number:** 0001427570
**File Stem:** 0001104659-25-060706
**Filing Date:** 2025-6
**Character Count:** 6005
**Document Hash:** bfd589190582c922974fbf3d7db67701
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-060706.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0001104659-25-060706

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250618

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ReShape Lifesciences Inc.
- **CENTRAL INDEX KEY:** 0001427570
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37897
- **FILM NUMBER:** 251057864

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673
- **BUSINESS PHONE:** 949-429-6680

**MAIL ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OBALON THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080220

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 18, 2025**

**RESHAPE LIFESCIENCES INC.**

(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**1-37897** | &nbsp;&nbsp;**1-37897** | &nbsp;&nbsp;**26-1828101** |
| &nbsp;&nbsp; (State or other jurisdiction <br> of incorporation) | &nbsp;&nbsp; (Commission <br> File Number) | &nbsp;&nbsp; (Commission <br> File Number) | &nbsp;&nbsp; (I.R.S. Employer <br> Identification Number) |
| &nbsp;&nbsp; **18 Technology Drive, Suite 110**<br> **Irvine, CA**  | &nbsp;&nbsp; **18 Technology Drive, Suite 110**<br> **Irvine, CA**  | &nbsp;&nbsp; <br> **92618** | &nbsp;&nbsp; <br> **92618** |
| &nbsp;&nbsp;(Address of principal executive offices) | &nbsp;&nbsp;(Address of principal executive offices) | &nbsp;&nbsp;(Zip Code) | &nbsp;&nbsp;(Zip Code) |

---

**(949) 429-6680**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) <br>

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) <br>

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) <br>

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of Class** | **Trading<br> Symbol** | **Name of Exchange on which Registered** |
| Common stock, $0.001 par value per share | RSLS | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 8.01 Other Events.**

As previously disclosed, on May 28, 2025, ReShape Lifesciences Inc. (the "Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company its securities are subject to delisting from Nasdaq based on the Company's continued non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity for continued listing.

As of March 31, 2025, the Company's stockholders' equity was $1.2 million. However (a) between June 3, 2025 and June 6, 2025, the Company sold 593,000 shares of common stock for gross proceeds of $3,642,564 pursuant to an equity distribution agreement with Maxim Group LLC in an "at-the-market" offering, as previously disclosed in the Company's prospectus supplement filed with the Securities and Exchange Commission ("SEC") on June 9, 2025 and (b) on June 9, 2025, the Company completed an offering of 1,054,604 shares of common stock for gross proceeds of $2,636,510, as previously disclosed in the Company's Form 8-K filed with the SEC on June 12, 2025. As a result, as of the date of this filing, the Company's stockholders' equity is greater than $2.5 million. The fact that the Company's stockholders' equity is currently in excess of the minimum required for continued listing on The Nasdaq Capital Market does not guarantee that the Company's securities will not be delisted from Nasdaq. The Company timely requested a hearing before a Nasdaq Hearings Panel, which will stay any suspension or delisting action pending the issuance of the Panel's decision following the hearing and the expiration of any additional extension period granted by the Panel.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **RESHAPE LIFESCIENCES INC.** | **RESHAPE LIFESCIENCES INC.** |
| By: | /s/ Paul F. Hickey |
|  | Paul F. Hickey |
|  | Chief Executive Officer |

---

Dated: June 18, 2025